Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.

ABSTRACT: The balance between safety and efficacy of T cell therapies remains challenging and T cell mediated toxicities have occurred. The stringent selection of tumor-specific targets and careful selection of tumor-specific T cells using T cell toxicity screenings are essential. In vitro screening options against vital organs or specialized cell subsets would be preferably included in preclinical pipelines, but options remain limited. Here, we set up preclinical models with human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes, epicardial cells, and kidney organoids to investigate toxicity risks of tumor-specific T cells more thoroughly. CD8+T cells reactive against PRAME, HA-1H, CD20, or WT1, currently used or planned to be used in phase I/II clinical studies, were included. U

SUBMITTER: van Amerongen RA 

PROVIDER: S-EPMC9931760 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature